Japan · Delayed Price · Currency is JPY Nxera Pharma Statistics
Total Valuation
Nxera Pharma has a market cap or net worth of JPY 89.93 billion. The enterprise value is 134.16 billion.
| Market Cap | 89.93B |
| Enterprise Value | 134.16B |
Important Dates
The next estimated earnings date is Friday, August 7, 2026.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nxera Pharma has 92.61 million shares outstanding. The number of shares has increased by 0.65% in one year.
| Current Share Class | 92.61M |
| Shares Outstanding | 92.61M |
| Shares Change (YoY) | +0.65% |
| Shares Change (QoQ) | +15.66% |
| Owned by Insiders (%) | 11.68% |
| Owned by Institutions (%) | 21.08% |
| Float | 70.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 18.09 |
| PS Ratio | 2.63 |
| PB Ratio | 1.41 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.92 |
| EV / EBITDA | 102.96 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.88.
| Current Ratio | 2.61 |
| Quick Ratio | 1.73 |
| Debt / Equity | 0.88 |
| Debt / EBITDA | 41.05 |
| Debt / FCF | -10.01 |
| Interest Coverage | -0.40 |
Financial Efficiency
Return on equity (ROE) is -15.26% and return on invested capital (ROIC) is -2.94%.
| Return on Equity (ROE) | -15.26% |
| Return on Assets (ROA) | -1.36% |
| Return on Invested Capital (ROIC) | -2.94% |
| Return on Capital Employed (ROCE) | -2.55% |
| Weighted Average Cost of Capital (WACC) | 7.40% |
| Revenue Per Employee | 96.69M |
| Profits Per Employee | -28.18M |
| Employee Count | 354 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 0.77 |
Taxes
In the past 12 months, Nxera Pharma has paid 226.00 million in taxes.
| Income Tax | 226.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.49% in the last 52 weeks. The beta is 0.21, so Nxera Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +8.49% |
| 50-Day Moving Average | 1,038.26 |
| 200-Day Moving Average | 932.99 |
| Relative Strength Index (RSI) | 44.50 |
| Average Volume (20 Days) | 846,890 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nxera Pharma had revenue of JPY 34.23 billion and -9.98 billion in losses. Loss per share was -110.34.
| Revenue | 34.23B |
| Gross Profit | 26.53B |
| Operating Income | -3.03B |
| Pretax Income | -9.75B |
| Net Income | -9.98B |
| EBITDA | 1.36B |
| EBIT | -3.03B |
| Loss Per Share | -110.34 |
Balance Sheet
The company has 11.60 billion in cash and 55.83 billion in debt, with a net cash position of -44.23 billion or -477.62 per share.
| Cash & Cash Equivalents | 11.60B |
| Total Debt | 55.83B |
| Net Cash | -44.23B |
| Net Cash Per Share | -477.62 |
| Equity (Book Value) | 63.69B |
| Book Value Per Share | 703.75 |
| Working Capital | 23.97B |
Cash Flow
In the last 12 months, operating cash flow was -4.94 billion and capital expenditures -643.00 million, giving a free cash flow of -5.58 billion.
| Operating Cash Flow | -4.94B |
| Capital Expenditures | -643.00M |
| Depreciation & Amortization | 4.39B |
| Net Borrowing | -16.02B |
| Free Cash Flow | -5.58B |
| FCF Per Share | -60.23 |
Margins
Gross margin is 77.50%, with operating and profit margins of -8.84% and -29.15%.
| Gross Margin | 77.50% |
| Operating Margin | -8.84% |
| Pretax Margin | -28.49% |
| Profit Margin | -29.15% |
| EBITDA Margin | 3.97% |
| EBIT Margin | -8.84% |
| FCF Margin | n/a |
Dividends & Yields
Nxera Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.65% |
| Shareholder Yield | -0.65% |
| Earnings Yield | -11.09% |
| FCF Yield | -6.20% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Nxera Pharma is 1,837.50, which is 86.74% higher than the current price. The consensus rating is "Buy".
| Price Target | 1,837.50 |
| Price Target Difference | 86.74% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 18.08% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
Nxera Pharma has an Altman Z-Score of 0.93 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.93 |
| Piotroski F-Score | 4 |